Get the Stockscreener App
12.89
4.60%
-0.59
Entrada Therapeutics Inc stock is traded at $12.89, with a volume of 48,717.
It is down -4.60% in the last 24 hours and down -25.45% over the past month.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.
See More
Previous Close:
$13.48
Open:
$13.5
24h Volume:
48,717
Relative Volume:
0.40
Market Cap:
$504.42M
Revenue:
$239.40M
Net Income/Loss:
$104.44M
P/E Ratio:
4.3547
EPS:
2.96
Net Cash Flow:
$-18.50M
1W Performance:
-4.32%
1M Performance:
-25.45%
6M Performance:
-6.88%
1Y Performance:
-7.15%
1-Day Range:
$12.79
$13.62
1-Week Range:
$12.53
$14.27
52-Week Range:
$11.35
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Name
Entrada Therapeutics Inc
Sector
Industry
Phone
857-305-1825
Address
ONE DESIGN CENTER PLACE, BOSTON
Compare TRDA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
12.86 | 504.42M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.71 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.75 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.50 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.37 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.79 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Jan-05-24 | Initiated | Oppenheimer | Outperform |
| Apr-03-23 | Initiated | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Stock (TRDA) Latest News
Entrada Therapeutics' (TRDA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
SG Americas Securities LLC Has $243,000 Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
BlackRock, Inc. Increases Stake in Entrada Therapeutics Inc - GuruFocus.com
Entrada Therapeutics advances Duchenne treatment study - MSN
Entrada Therapeutics Inc.: Promising Therapeutic Potential and Favorable Valuation Amidst Risks - TipRanks
H.C. Wainwright maintains $20 target on Entrada Therapeutics stock - Investing.com India
Entrada Therapeutics Gets UK Approval for Phase 1/2 Study of Duchenne Muscular Dystrophy Treatment - Marketscreener.com
Entrada Therapeutics Advances Duchenne Muscular Dystrophy Trial - TipRanks
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy - The Manila Times
Duchenne Muscular Dystrophy Breakthrough: Entrada's Novel Treatment Advances After Promising Safety Results - StockTitan
Azenta Announces the Election of Dipal Doshi to its Board of Directors - PR Newswire
(TRDA) Proactive Strategies - Stock Traders Daily
Pompe Disease Pipeline 2024: Mechanism of Action, Route of Administration, and Clinical Trial Insights Explored by DelveInsight | M6P Therapeutics, Entrada Therapeutics, Maze Therapeutics, Astellas - The Globe and Mail
Barclays PLC Buys 30,585 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Barclays PLC Acquires 30,585 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics : Corporate Presentation -January 15, 2025 at 04:41 pm EST - Marketscreener.com
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Jane Street Group LLC - Defense World
The Market Doesn't Like What It Sees From Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Revenues Yet As Shares Tumble 26% - Simply Wall St
Entrada Therapeutics (NASDAQ:TRDA) Trading Down 7.6%Here's Why - MarketBeat
Geode Capital Management LLC Raises Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Geode Capital Management LLC Has $9.21 Million Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Barclays PLC Increases Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Bought by Barclays PLC - MarketBeat
Best Momentum Stocks to Buy for December 30th - Yahoo Finance
State Street Corp Has $7.50 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Where are the Opportunities in (TRDA) - Stock Traders Daily
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com
Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why - MSN
Charles Schwab Investment Management Inc. Has $2.97 Million Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
XTX Topco Ltd Takes $634,000 Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Fmr LLC - MarketBeat
Is Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Stock Performance Tethered To Its Strong Fundamentals? - Simply Wall St
Entrada Therapeutics (NASDAQ:TRDA) Upgraded at Roth Capital - Defense World
Roth Mkm Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating - Yahoo Finance
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Janus Henderson Group PLC - MarketBeat
Jacobs Levy Equity Management Inc. Has $3.23 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Insider Sell Alert: Natarajan Sethuraman Sells Shares of Entrada Therapeutics Inc (TRDA) - GuruFocus.com
Entrada Therapeutics CFO sells shares worth nearly $120,000 By Investing.com - Investing.com Nigeria
Entrada Therapeutics president sells $320,619 in stock By Investing.com - Investing.com Nigeria
Entrada Therapeutics CFO sells shares worth nearly $120,000 - Investing.com India
Entrada Therapeutics president sells $320,619 in stock - Investing.com
Entrada Therapeutics stock hits 52-week high at $20.5 By Investing.com - Investing.com Canada
Massachusetts Financial Services Co. MA Invests $1.11 Million in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Myotonic Dystrophy Clinical Trial Pipeline Boom as Over 20 Companies Leading the Charge in Research and Development | DelveInsight - PR Newswire
Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
Entrada Therapeutics Inc Stock (TRDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Entrada Therapeutics Inc Stock (TRDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Dec 11 '24 |
Sale |
20.23 |
21,787 |
440,751 |
4,381,062 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Dec 10 '24 |
Sale |
20.77 |
22,935 |
476,360 |
4,402,849 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Dec 11 '24 |
Sale |
20.23 |
21,787 |
440,751 |
4,381,062 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Dec 02 '24 |
Option Exercise |
2.10 |
5,000 |
10,500 |
78,849 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
2.10 |
1,000 |
2,100 |
74,849 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Dec 02 '24 |
Sale |
20.00 |
5,000 |
99,978 |
73,849 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Nov 29 '24 |
Sale |
19.97 |
1,000 |
19,970 |
73,849 |
| Sethuraman Natarajan | President, Research & Develop. |
Dec 03 '24 |
Sale |
20.15 |
11,703 |
235,786 |
144,997 |
| Sethuraman Natarajan | President, Research & Develop. |
Dec 02 '24 |
Sale |
20.26 |
4,088 |
82,834 |
156,700 |
| Sethuraman Natarajan | President, Research & Develop. |
Nov 29 '24 |
Sale |
20.00 |
100 |
2,000 |
160,788 |
1.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):